
|Videos|March 20, 2014
The Utility of Hyperthermic Intraperitoneal Chemotherapy
Author(s)Valerie Francescutti, MD, FRCSC
Valerie Francescutti, MD, FRCSC, assistant professor, Surgical Oncology, Roswell Park Cancer Institute (RPCI), discusses the utility of hyperthermic intraperitoneal chemotherapy (HIPEC).
Advertisement
Clinical Pearls
Valerie Francescutti, MD, FRCSC, assistant professor, Surgical Oncology, Roswell Park Cancer Institute (RPCI), discusses the utility of hyperthermic intraperitoneal chemotherapy (HIPEC).
- HIPEC involves removing all cancer from a patient’s abdominal cavity and providing heated chemotherapy for the management of any microscopic tumors
- Indications for HIPEC include colorectal cancer that has resulted in peritoneal metastases, appendiceal cancer, and peritoneal mesothelioma
- At RPCI, 50-60% of patients treated with HIPEC have appendiceal or colorectal cancers
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Daratumumab for Smoldering Multiple Myeloma
2
Trial Data Show Efficacy, Tolerability of Nivolumab Plus Visogromab in MIBC
3
FDA Grants Orphan Drug Status to Novel CD33-Directed Immunotherapy for AML
4
Domvanalimab Combo Shows Enriched First-Line Efficacy in Advanced GI Cancers
5








































